---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-22-000023"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:30:49.879497+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards Q3 sales $1.32B; adjusted EPS $0.61 (up 13% YoY); cuts FY22 adjusted EPS guidance to $2.40-$2.50

## Summary
- GAAP EPS $0.55, adjusted EPS $0.61; $0.07/share charge from discontinuing HARPOON surgical mitral repair.
- TAVR sales $862M (+1% reported, +6% cc); TMTT sales $30M; U.S. procedures grew mid-single digits YoY.
- 2022 adjusted EPS guidance revised to $2.40-$2.50 from prior $2.50-$2.65 range; total sales now expected at low end of $5.35-$5.55B.
- Received U.S. FDA and CE Mark for PASCAL Precision; U.S. FDA approval for SAPIEN 3 Ultra RESILIA valve.
- Q3 free cash flow $250M; cash and investments $1.7B as of Sept. 30, 2022.

## SEC filing metadata
- accession: 0001099800-22-000023
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/0001099800-22-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/ew-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-22-000023
- JSON: https://secwatch.observer/filing/0001099800-22-000023.json
- Plain text: https://secwatch.observer/filing/0001099800-22-000023.txt

## Key facts
- Earnings Releases
  Edwards Lifesciences Corp updated its quarter ended September 30, 2022 guidance (lowered).
  - Period: quarter ended September 30, 2022
  - Guidance: lowered
  - Result: reported results
  source text: On October 27, 2022, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/0001099800-22-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.